ACLARION, INC(ACON),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

ACON ACLARION, INC

Market Closed 12-12 16:00:00 EST

6.44

+0.33

+5.40%

盘后6.33

-0.11-1.71%

19:53 EST

High6.53	Low6.15	Vol110.61K
Open6.47	D1 Closing6.11	Amplitude6.22%
Mkt Cap4.32M	Tradable Cap4.32M	Total Shares671.40K
T/O717.60K	T/O Rate16.48%	Tradable Shares671.30K
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"ACON","market":"US","secType":"STK","nameCN":"ACLARION, INC","latestPrice":6.44,"timestamp":1765573200000,"preClose":6.11,"halted":0,"volume":110614,"hourTrading":{"tag":"盘后","latestPrice":6.33,"preClose":6.44,"latestTime":"19:53 EST","volume":2571,"amount":16485.3066,"timestamp":1765587236727},"delay":0,"floatShares":671300,"shares":671400,"eps":-12.123368,"marketStatus":"Market Closed","change":0.33,"latestTime":"12-12 16:00:00 EST","open":6.47,"high":6.53,"low":6.15,"amount":717601.0687216,"amplitude":0.062193,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":0,"etf":0,"ttmEps":-12.123368,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1765789200000},"marketStatusCode":7,"adr":0,"listingDate":1650600000000,"exchange":"NASDAQ","adjPreClose":6.11,"preHourTrading":{"tag":"盘前","latestPrice":6.69,"preClose":6.11,"latestTime":"09:25 EST","volume":15328,"amount":104971.232896,"timestamp":1765549509640},"postHourTrading":{"tag":"盘后","latestPrice":6.33,"preClose":6.44,"latestTime":"19:53 EST","volume":2571,"amount":16485.3066,"timestamp":1765587236727},"volumeRatio":0.8687876774989771},"requestUrl":"/m/hq/s/ACON/wiki","defaultTab":"wiki","newsList":[{"id":"2588888882","title":"Aclarion Nociscan Study Published in Leading Spine Surgery Journal","url":"https://stock-news.laohu8.com/highlight/detail?id=2588888882","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588888882?lang=en_us&edition=fundamental","pubTime":"2025-12-04 21:11","pubTimestamp":1764853914,"startTime":"0","endTime":"0","summary":"Aclarion Inc. has announced the publication of a featured article on its Nociscan technology in the Special Pain Issue of the International Journal of Spine Surgery . The article highlights a successful clinical case in which Nociscan, a noninvasive SaaS platform, was used alongside traditional MRI to more accurately identify the source of chronic low back pain in a patient. As a result, the surgeon was able to limit surgical intervention to the affected disc, leading to the elimination of the patient's pain and a full return to an active lifestyle. These results, which strengthen the clinical evidence supporting Nociscan, have already been published in advance online by the IJSS.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Aclarion","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251204:nNDL4p81Z:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4167","ACON"],"gpt_icon":0},{"id":"2588505348","title":"Press Release: Aclarion Appoints Jason Brosniak as Commercial Director to Drive Adoption and Market Expansion in the Eastern U.S.","url":"https://stock-news.laohu8.com/highlight/detail?id=2588505348","media":"Dow Jones","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588505348?lang=en_us&edition=fundamental","pubTime":"2025-12-02 21:00","pubTimestamp":1764680400,"startTime":"0","endTime":"0","summary":"-- Proven commercial leader with 20+ years of experience driving revenue. growth and market adoption for early-stage and high-growth MedTech. Jason is a proven commercial leader with more than 20 years of experience accelerating revenue growth and building high-performing teams for high-growth MedTech companies, including roles at Relievant Medsystems , Kyphon , and Intrinsic Therapeutics. His background in successfully launching breakthrough technologies and establishing new market categories across spine, orthopedics, and pain management makes him exceptionally well-positioned to drive the adoption of Nociscan in the Eastern U.S.\"Jason's hire represents another significant commercial milestone for the Company,\" said Brent Ness, CEO of Aclarion. \"The growing demand for Nociscan through real-world evidence trials, and the national CLARITY randomized controlled trial, necessitates additional commercial resources in the densely populated Eastern U.S. Jason brings the critical early-stage","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4167","BK4161","EML","ACON"],"gpt_icon":0},{"id":"2588570518","title":"Aclarion CEO Brent Ness Reports Acquisition of Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2588570518","media":"Reuters","labels":["shareholding","insiderTrades","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588570518?lang=en_us&edition=fundamental","pubTime":"2025-12-02 06:00","pubTimestamp":1764626430,"startTime":"0","endTime":"0","summary":"Brent Ness, Chief Executive Officer and Director of Aclarion Inc., reported the acquisition of common shares of the company. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Aclarion Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on December 01, 2025, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251201:nNDL6RbYM3:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Aclarion CEO Brent Ness Reports Acquisition of Common Shares","news_tag":"shareholding,insiderTrades,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4167","ACON"],"gpt_icon":0},{"id":"2584154138","title":"Aclarion Is Maintained at Buy by Ascendiant Capital","url":"https://stock-news.laohu8.com/highlight/detail?id=2584154138","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584154138?lang=en_us&edition=fundamental","pubTime":"2025-11-20 18:51","pubTimestamp":1763635860,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/ACON/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  November 20, 2025 05:51 ET (10:51 GMT)","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ACON","BK4167"],"gpt_icon":0},{"id":"2582374728","title":"Aclarion Q3 EPS $(2.93) Misses $(2.62) Estimate, Sales $18.942K Miss $40.000K Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2582374728","media":"Benzinga","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582374728?lang=en_us&edition=fundamental","pubTime":"2025-11-12 21:52","pubTimestamp":1762955533,"startTime":"0","endTime":"0","summary":"Aclarion (NASDAQ:ACON) reported quarterly losses of $(2.93) per share which missed the analyst consensus estimate of $(2.62) by 11.83 percent. This is a 99.8 percent increase over losses of $(1.50 thousand) per share","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/25/11/48801864/aclarion-q3-eps-2-93-misses-2-62-estimate-sales-18-942k-miss-40-000k-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ACON","BK4167"],"gpt_icon":0},{"id":"2581238437","title":"Press Release: Aclarion Appoints Dan Isherwood as UK Commercial Director to Drive Adoption and Market Expansion","url":"https://stock-news.laohu8.com/highlight/detail?id=2581238437","media":"Dow Jones","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581238437?lang=en_us&edition=fundamental","pubTime":"2025-11-05 19:00","pubTimestamp":1762340400,"startTime":"0","endTime":"0","summary":"-- Marks Aclarion's first commercial sales hire with seasoned HealthTech. leader and proven track record of advancing musculoskeletal imaging and. -- Experiencing strong commercial traction in UK as first market worldwide. \"Dan's hire represents a significant commercial milestone for the Company,\" said Brent Ness, CEO of Aclarion. \"The UK represents the first market where physicians can order Nociscan for their patients without navigating the friction around who is going to pay for the scan. With this barrier gone for over 5 million patients in the UK, combined with our partnership with The London Clinic, and now the addition of Dan as the Company's first dedicated hire focused on driving scan volume, we are excited to see how this builds on the strong early growth we are already seeing in the UK market.\". Dan joins Aclarion following an accomplished career that spans key roles in advanced imaging and spine technology at industry leaders, including J&J MedTech , EOS Imaging , and NuVas","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4167","ACON"],"gpt_icon":0},{"id":"2575532299","title":"BRIEF-Aclarion Inc - Clarity Trial On Schedule, Early Readouts Expected Q2 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2575532299","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2575532299?lang=en_us&edition=fundamental","pubTime":"2025-10-14 18:34","pubTimestamp":1760438073,"startTime":"0","endTime":"0","summary":"BRIEF-Aclarion Inc - Clarity Trial On Schedule, Early Readouts Expected Q2 2026Oct 14 (Reuters) - Aclarion Inc ACON.O:ACLARION INC - CLARITY TRIAL ON SCHEDULE, EARLY READOUTS EXPECTED Q2 2026Source text: ID:nGNX4cJbhjFurther company coverage: ACON.O ((Reuters.Briefs@thomsonreuters.com;))","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251014:nFWN3VV1EL:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ACON","BK4167"],"gpt_icon":0},{"id":"2575951142","title":"Aclarion Inc. Announces $2.5 Million Registered Direct Offering of 64,000 Shares and Pre-Funded Warrants for 236,000 Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2575951142","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2575951142?lang=en_us&edition=fundamental","pubTime":"2025-10-14 18:06","pubTimestamp":1760436384,"startTime":"0","endTime":"0","summary":"Aclarion Inc. has entered into a Securities Purchase Agreement with unnamed purchasers to sell a total of 64,000 shares of common stock at $8.36 per share and pre-funded warrants to purchase up to 236,000 shares of common stock. The transactions are expected to generate approximately $2.5 million in gross proceeds before fees and expenses. Dawson James Securities, Inc. is acting as the exclusive placement agent for the offering.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Aclarion Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on October 14, 2025, and is solely responsible for the i","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251014:nNDL3N7RDD:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4167","ACON"],"gpt_icon":0},{"id":"2574589121","title":"Aclarion Inc to Present at LD Micro Main Event XIX","url":"https://stock-news.laohu8.com/highlight/detail?id=2574589121","media":"Reuters","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2574589121?lang=en_us&edition=fundamental","pubTime":"2025-10-09 18:01","pubTimestamp":1760004063,"startTime":"0","endTime":"0","summary":"Aclarion Inc., a healthcare technology company specializing in biomarkers and AI algorithms to help physicians identify the location of chronic low back pain, will present at the LD Micro Main Event XIX on Monday, October 20, 2025, at 12:00 PM PT in San Diego, California. Executive Chairman Jeff Thramann and CEO Brent Ness will lead the presentation.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Aclarion Inc. published the original content used to generate this news brief via Newsfile  on October 09, 2025, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251009:nNDLvT6Lg:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ACON","BK4167"],"gpt_icon":0},{"id":"2570685093","title":"BRIEF-First Patients Enrolled at UHealth – University of Miami in Aclarion’s Pivotal CLARITY Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2570685093","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2570685093?lang=en_us&edition=fundamental","pubTime":"2025-09-25 18:04","pubTimestamp":1758794649,"startTime":"0","endTime":"0","summary":"BRIEF-First Patients Enrolled at UHealth – University of Miami in Aclarion’s Pivotal CLARITY TrialSept 25 (Reuters) - Aclarion Inc ACON.O:FIRST PATIENTS ENROLLED AT UHEALTH – UNIVERSITY OF MIAMI IN AC","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250925:nTUABY4KJY:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ACONW","ACON","BK4167"],"gpt_icon":0},{"id":"2570098070","title":"Aclarion: Enrollment Remains on Track With Internal Interim Results Expected in Q2 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2570098070","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2570098070?lang=en_us&edition=fundamental","pubTime":"2025-09-25 18:00","pubTimestamp":1758794401,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250925:nTUABY4KJY:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ACON","BK4167","ACONW"],"gpt_icon":0},{"id":"2568255774","title":"Aclarion Is Maintained at Buy by Ascendiant Capital","url":"https://stock-news.laohu8.com/highlight/detail?id=2568255774","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2568255774?lang=en_us&edition=fundamental","pubTime":"2025-09-19 16:40","pubTimestamp":1758271200,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/ACON/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  September 19, 2025 04:40 ET (08:40 GMT)","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ACON","BK4167"],"gpt_icon":0},{"id":"2564146233","title":"Aclarion Inc. Files Initial Statement of Beneficial Ownership for CFO Gregory A. Gould","url":"https://stock-news.laohu8.com/highlight/detail?id=2564146233","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2564146233?lang=en_us&edition=fundamental","pubTime":"2025-09-04 05:05","pubTimestamp":1756933556,"startTime":"0","endTime":"0","summary":"Aclarion Inc. has filed an initial statement of beneficial ownership with the U.S. Securities and Exchange Commission. The filing lists Gregory A. Gould as the beneficial owner, who holds the position of Chief Financial Officer  at the company. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Aclarion Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on September 03, 2025, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250903:nNDL362pwx:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4167","ACON"],"gpt_icon":0},{"id":"2564364525","title":"Aclarion Inc - Greg Gould Succeeds John Lorbiecki as CFO","url":"https://stock-news.laohu8.com/highlight/detail?id=2564364525","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2564364525?lang=en_us&edition=fundamental","pubTime":"2025-09-03 18:00","pubTimestamp":1756893600,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250903:nTUA70FQN3:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ACON","ACONW","BK4167"],"gpt_icon":0},{"id":"2564646943","title":"Press Release: Aclarion Appoints Greg Gould as Chief Financial Officer","url":"https://stock-news.laohu8.com/highlight/detail?id=2564646943","media":"Dow Jones","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2564646943?lang=en_us&edition=fundamental","pubTime":"2025-09-03 18:00","pubTimestamp":1756893600,"startTime":"0","endTime":"0","summary":"HealthTech CFO with extensive public company experience building organizations for growth and value creation. Demonstrated success in raising capital, driving profitability, and scaling operations to $500M revenue while ensuring compliance and strengthening financial integrity. \"We are thrilled to welcome Greg to our leadership team. His deep expertise in driving growth, capital strategies and financial leadership at publicly-traded companies will be invaluable as we execute on our vision of making Nociscan more widely available to physicians and patients with chronic low back pain,\" said Brent Ness, Chief Executive Officer of Aclarion. \"We thank John for his leadership and instrumental role in establishing the strong financial foundation for the company which has positioned us well for long-term success.\". \"I'm excited to join Aclarion at such a pivotal time in its growth,\" said Gould. \"The chance to build on the Company's recent momentum and help scale the business is incredibly comp","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CPA","LU1236620750.USD","ACON","BK4167","BK4500","BK4008","LU1236620834.HKD","CFO"],"gpt_icon":0},{"id":"2559596752","title":"Aclarion Q2 EPS $(2.75) Misses $(2.26) Estimate, Sales $19.319K Miss $30.000K Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2559596752","media":"Benzinga","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2559596752?lang=en_us&edition=fundamental","pubTime":"2025-08-15 05:44","pubTimestamp":1755207891,"startTime":"0","endTime":"0","summary":"Aclarion (NASDAQ:ACON) reported quarterly losses of $(2.75) per share which missed the analyst consensus estimate of $(2.26) by 21.68 percent. This is a 99.8 percent increase over losses of $(1.36 thousand) per share","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/25/08/47142917/aclarion-q2-eps-2-75-misses-2-26-estimate-sales-19-319k-miss-30-000k-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":"Aclarion Q2 EPS $(2.75) Misses $(2.26) Estimate, Sales $19.319K Miss $30.000K Estimate","news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ACON"],"gpt_icon":0},{"id":"2557396489","title":"BRIEF-Aclarion Reaffirms Cash Runway Through Q3 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2557396489","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2557396489?lang=en_us&edition=fundamental","pubTime":"2025-08-05 19:46","pubTimestamp":1754394406,"startTime":"0","endTime":"0","summary":"BRIEF-Aclarion Reaffirms Cash Runway Through Q3 2026Aug 5 (Reuters) - Aclarion Inc ACON.O:ACLARION INC - REAFFIRMS CASH RUNWAY THROUGH Q3 2026Source text: ID:nGNXJdYFNFurther company coverage: ACON.O ((Reuters.Briefs@thomsonreuters.com;))","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250805:nFWN3TX0KT:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4167","ACONW","ACON"],"gpt_icon":0},{"id":"2553409461","title":"Aclarion Inc. Conducted Its Annual Stockholders Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2553409461","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2553409461?lang=en_us&edition=fundamental","pubTime":"2025-07-22 04:04","pubTimestamp":1753128244,"startTime":"0","endTime":"0","summary":"Aclarion Inc. held its 2025 Annual Meeting of Stockholders on July 21, 2025. During the meeting, seven directors were elected to serve on the board. The appointment of Haynie & Company as the independent registered accounting firm was ratified. A proposed reverse stock split was approved, while an amendment to the 2022 equity incentive plan was not approved.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Aclarion Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on July 21, 2025, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250721:nNDL1hHCdC:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ACON","BK4167"],"gpt_icon":0},{"id":"2549572625","title":"Press Release: Aclarion, Inc. Announces Adjournment of Annual Meeting of Stockholders","url":"https://stock-news.laohu8.com/highlight/detail?id=2549572625","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2549572625?lang=en_us&edition=fundamental","pubTime":"2025-07-08 04:01","pubTimestamp":1751918460,"startTime":"0","endTime":"0","summary":"-- Meeting adjourned to Monday, July 21, 2025 at 9:30 a.m. Mountain Time. BROOMFIELD, Colo., July 07, 2025  -- Aclarion, Inc.  , a healthcare technology company that leverages Magnetic Resonance Spectroscopy , artificial intelligence and a proprietary biomarker to optimize clinical treatments for low back and neck pain, today announced that its Annual Meeting of Stockholders  scheduled for July 7, 2025 has been adjourned for the purpose of soliciting additional votes with respect to the proposals described in the Company's definitive proxy statement for the Annual Meeting, filed with the Securities and Exchange Commission  on May 13, 2025.Aclarion is a healthcare technology company that leverages Magnetic Resonance Spectroscopy , and a proprietary biomarker to optimize clinical treatments. Aclarion's technology addresses the $134.5B U.S. low back and neck pain market. The Company is currently utilizing Artificial Intelligence  to assist in quality control processes that flag spectrosco","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ACON","BK4167","ACONU"],"gpt_icon":0},{"id":"2546545216","title":"BRIEF-First Patient Enrolled In Aclarion’S Groundbreaking Clarity Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2546545216","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2546545216?lang=en_us&edition=fundamental","pubTime":"2025-06-25 18:02","pubTimestamp":1750845723,"startTime":"0","endTime":"0","summary":"BRIEF-First Patient Enrolled In Aclarion’S Groundbreaking Clarity TrialJune 25 (Reuters) - Aclarion Inc ACON.O:FIRST PATIENT ENROLLED IN ACLARION’S GROUNDBREAKING CLARITY TRIALACLARION INC - ACCLARION","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250625:nTUA1MSMR0:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ACON","ACONW","BK4167"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.aclarion.com","stockEarnings":[{"period":"1week","weight":0.0489},{"period":"1month","weight":-0.066},{"period":"3month","weight":-0.1658},{"period":"6month","weight":-0.1344},{"period":"1year","weight":-0.9938},{"period":"ytd","weight":-0.9951}],"compareEarnings":[{"period":"1week","weight":-0.0057},{"period":"1month","weight":-0.0024},{"period":"3month","weight":0.037},{"period":"6month","weight":0.142},{"period":"1year","weight":0.1281},{"period":"ytd","weight":0.1633}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Aclarion, Inc., a healthcare technology company, leverages for Magnetic Resonance Spectroscopy (MRS) in the United States. It develops NOCISCAN Post-Processor suite of software applications comprising NOCICALC that receives the raw un-processed NOCISCAN MRS exam data and post-processes that raw data into final spectra and performs various degenerative pain biomarker; and NOCIGRAM, a clinical decision support software. The company was formerly known as Nocimed, Inc. and changed its name to Aclarion, Inc. in December 2021. Aclarion, Inc. was incorporated in 2008 and is based in Broomfield, Colorado.","yearOnYearQuotes":[{"month":1,"riseRate":0.333333,"avgChangeRate":-0.328009},{"month":2,"riseRate":0.333333,"avgChangeRate":-0.412872},{"month":3,"riseRate":0,"avgChangeRate":-0.387274},{"month":4,"riseRate":0,"avgChangeRate":-0.174468},{"month":5,"riseRate":0.5,"avgChangeRate":0.044825},{"month":6,"riseRate":0.25,"avgChangeRate":-0.115199},{"month":7,"riseRate":0.5,"avgChangeRate":-0.021585},{"month":8,"riseRate":0.5,"avgChangeRate":-0.066272},{"month":9,"riseRate":0.25,"avgChangeRate":-0.18466},{"month":10,"riseRate":1,"avgChangeRate":0.110748},{"month":11,"riseRate":0,"avgChangeRate":-0.1724},{"month":12,"riseRate":0.25,"avgChangeRate":-0.169412}],"exchange":"NASDAQ","name":"ACLARION, INC","nameEN":"ACLARION, INC"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.11","shortVersion":"4.35.11","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"ACLARION, INC(ACON),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest ACLARION, INC(ACON) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"ACLARION, INC,ACON,ACLARION, INC股票,ACLARION, INC股票老虎,ACLARION, INC股票老虎国际,ACLARION, INC行情,ACLARION, INC股票行情,ACLARION, INC股价,ACLARION, INC股市,ACLARION, INC股票价格,ACLARION, INC股票交易,ACLARION, INC股票购买,ACLARION, INC股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"ACLARION, INC(ACON),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest ACLARION, INC(ACON) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction